Render Target: STATIC
Render Timestamp: 2024-11-08T10:00:38.370Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:57:17.190
Product last modified at: 2024-10-17T19:15:08.795Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

IDH2 (KrMab-3) Mouse mAb #60322

Filter:
  • WB
  • IP
  • IHC
  • IF
  • F

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 43
    Source/Isotype Mouse IgG2b
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    • IHC-Immunohistochemistry 
    • IF-Immunofluorescence 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50
    Immunohistochemistry (Paraffin) 1:50 - 1:200
    Immunofluorescence (Immunocytochemistry) 1:50
    Flow Cytometry (Fixed/Permeabilized) 1:50 - 1:200

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    IDH2 (KrMab-3) Mouse mAb recognizes endogenous levels of total IDH2 protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala174 of human IDH2 protein, as described by Kaneko et al. (2013) [8].

    Background

    IDH2 is one of three isocitrate dehydrogenases (IDH1-3) that catalyze the oxidative decarboxylation of isocitrate to produce CO2 and α-ketoglutarate (α-KG). These enzymes belong to two distinct subclasses that utilize either NAD or NADP+ as an electron acceptor. IDH2 is an NADP+-dependent isocitrate dehydrogenase expressed primarily in the mitochondria, where it also functions in the TCA cycle (1,2). Mutations in IDH2 or its cytoplasmic counterpart (IDH1) have been reported in glioblastoma multiforme (3), acute myeloid leukemia (4,5), and other malignancies (6). Research studies have shown that gain-of-function mutations in IDH2 can lead to the accumulation and secretion of the oncometabolite R-2-hydroxyglutarate (2HG) in cancer cells (6,7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalStain is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.